OCM
VRTX icon

Osbon Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Osbon Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496 Hold
1
– – ﹤0.01% 411
2026
Q1 		$447 Hold
1
– – ﹤0.01% 475
2025
Q4 		$453 Buy
+1
New +$431 ﹤0.01% 340

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Osbon Capital Management's VRTX Position: Q2 2026 in Review

Osbon Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1 share worth $496. The position accounts for ﹤0.01% of the portfolio, ranked #411.

Osbon Capital Management first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Osbon Capital Management held 1 share of Vertex Pharmaceuticals worth $496 as of Q2 2026.
  • Osbon Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Osbon Capital Management's portfolio in Q2 2026, its #411 holding.
  • Osbon Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Osbon Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.